Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom: Design of a prospective observational study

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Koekkoek, Johan A F ^a,b   Kerkhof, Melissa ^b   Dirven, Linda ^a   Heimans, Jan J ^a   Postma, Tjeerd J ^a   Vos, Maaike J ^b   Bromberg, Jacoline E C ^c   van den Bent, Martin J ^c   Reijneveld, Jaap C ^a   Taphoorn, Martin J B ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Antiepileptic drugs; Brain tumour; Drug withdrawal; Epilepsy; Glioma; Medication management; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CORTICOSTEROID; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; ASTROCYTOMA; BRAIN RADIATION; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DECISION MAKING; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPENDYMOMA; EPILEPSY; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MENINGIOMA; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NETHERLANDS; NEUROLOGIC DISEASE; NEUROSURGERY; OBSERVATIONAL STUDY; OLIGODENDROGLIOMA; PROSPECTIVE STUDY; RECURRENT DISEASE; SEIZURE; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; SUBEPENDYMOMA; TREATMENT DURATION; TUMOR GROWTH; YOUNG ADULT; COMPLICATION; METHODOLOGY; SEIZURES;

ANTICONVULSANTS; BRAIN NEOPLASMS; GLIOMA; HUMANS; PROSPECTIVE STUDIES; RESEARCH DESIGN; SEIZURES;

EID: 84908056481     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-014-0157-4     Document Type: Article

References (41)

1. Weller M, Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to do about it?. Lancet Oncol 2012, 13:e375-e382. 10.1016/S1470-2045(12)70266-8, 22935237.
2. Ruda R, Bello L, Duffau H, Soffietti R. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol 2012, 14(Suppl 4):iv55-iv64. 10.1093/neuonc/nos199, 23095831.
3. Pallud J, Audureau E, Blonski M, Sanai N, Bauchet L, Fontaine D, Mandonnet E, Dezamis E, Psimaras D, Guyotat J, Peruzzi P, Page P, Gal B, Parraga E, Baron MH, Vlaicu M, Guillevin R, Devaux B, Duffau H, Taillandier L, Capelle L, Huberfeld G. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014, 137:449-462. 10.1093/brain/awt345, 24374407.
4. Smits A, Duffau H. Seizures and the natural history of World Health Organization Grade II gliomas: a review. Neurosurgery 2011, 68:1326-1333. 21307795.
5. Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D, Cairncross G. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 1997, 15:1294-1301. 9193320.
6. Rosati A, Tomassini A, Pollo B, Ambrosi C, Schwarz A, Padovani A, Bonetti B. Epilepsy in cerebral glioma: timing of appearance and histological correlations. J Neurooncol 2009, 93:395-400. 10.1007/s11060-009-9796-5, 19183850.
7. Thom M, Toma A, An S, Martinian L, Hadjivassiliou G, Ratilal B, Dean A, McEvoy A, Sisodiya SM, Brandner S. One hundred and one dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular genetic, and clinical correlations and a review of the literature. J Neuropathol Exp Neurol 2011, 70:859-878. 21937911.
8. Compton JJ, Laack NN, Eckel LJ, Schomas DA, Giannini C, Meyer FB. Long-term outcomes for low-grade intracranial ganglioglioma: 30-year experience from the Mayo Clinic. J Neurosurg 2012, 117:825-830. 10.3171/2012.7.JNS111260, 22957524.
9. Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas. Epilepsia 2013, 54(Suppl 9):12-17. 10.1111/epi.12437, 24328866.
10. Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro Oncol 2012, 14(Suppl 4):iv17-iv24. 10.1093/neuonc/nos161, 23095826.
11. Aaronson NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN, Slotman BJ, Klein M. Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol 2011, 29:4430-4435. 10.1200/JCO.2011.35.5750, 22010018.
12. Klein M, Engelberts NH, van der Ploeg HM, Kasteleijn-Nolst Trenite DG, Aaronson NK, Taphoorn MJ, Baaijen H, Vandertop WP, Muller M, Postma TJ, Heimans JJ. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 2003, 54:514-520. 10.1002/ana.10712, 14520665.
13. van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 2009, 256:1519-1526. 10.1007/s00415-009-5156-9, 19434440.
14. Englot DJ, Berger MS, Barbaro NM, Chang EF. Predictors of seizure freedom after resection of supratentorial low-grade gliomas. A review. J Neurosurg 2011, 115:240-244. 10.3171/2011.3.JNS1153, 21529134.
15. Englot DJ, Han SJ, Berger MS, Barbaro NM, Chang EF. Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors. Neurosurgery 2012, 70:921-928. 10.1227/NEU.0b013e31823c3a30, 21997540.
16. Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, Berger MS. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008, 108:227-235. 10.3171/JNS/2008/108/2/0227, 18240916.
17. You G, Sha ZY, Yan W, Zhang W, Wang YZ, Li SW, Sang L, Wang Z, Li GL, Li SW, Song YJ, Kang CS, Jiang T. Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro Oncol 2012, 14:230-241. 10.1093/neuonc/nor205, 22187341.
18. Luyken C, Blumcke I, Fimmers R, Urbach H, Elger CE, Wiestler OD, Schramm J. The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia 2003, 44:822-830. 10.1046/j.1528-1157.2003.56102.x, 12790896.
19. Southwell DG, Garcia PA, Berger MS, Barbaro NM, Chang EF. Long-term seizure control outcomes after resection of gangliogliomas. Neurosurgery 2012, 70:1406-1413. 10.1227/NEU.0b013e3182500a4c, 22353798.
20. van den Bent MJ, Afra D, De WO, Ben HM, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, Karim AB. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005, 366:985-990. 10.1016/S0140-6736(05)67070-5, 16168780.
21. Sherman JH, Moldovan K, Yeoh HK, Starke RM, Pouratian N, Shaffrey ME, Schiff D. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg 2011, 114:1617-1621. 10.3171/2010.12.JNS101602, 21235313.
22. Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003, 14:1722-1726. 10.1093/annonc/mdg502, 14630675.
23. Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 2007, 68:1831-1836. 10.1212/01.wnl.0000262034.26310.a2, 17515545.
24. Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V, Brandes AA. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 2008, 89:179-185. 10.1007/s11060-008-9600-y, 18431544.
25. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 2003, 14:1715-1721. 10.1093/annonc/mdg371, 14630674.
26. Taillandier L, Duffau H. Epilepsy and insular Grade II gliomas: an interdisciplinary point of view from a retrospective monocentric series of 46 cases. Neurosurg Focus 2009, 27:E8. 10.3171/2009.6.FOCUS09102, 19757989.
27. Menon R, Rathore C, Sarma SP, Radhakrishnan K. Feasibility of antiepileptic drug withdrawal following extratemporal resective epilepsy surgery. Neurology 2012, 79:770-776. 10.1212/WNL.0b013e3182644f7d, 22843256.
28. Afshari D, Moradian N. Evaluating the rate of recurrence of epilepsy after therapy discontinuation in 2-year seizure-free epileptic patients. Int J Neurosci 2012, 122:598-601. 22612672.
29. Rathore C, Panda S, Sarma PS, Radhakrishnan K. How safe is it to withdraw antiepileptic drugs following successful surgery for mesial temporal lobe epilepsy?. Epilepsia 2011, 52:627-635. 10.1111/j.1528-1167.2010.02890.x, 21219315.
30. Ladino LD, Hernandez-Ronquillo L, Tellez-Zenteno JF. Management of antiepileptic drugs following epilepsy surgery: a meta-analysis. Epilepsy Res 2014, 108:765-774. 10.1016/j.eplepsyres.2014.01.024, 24613746.
31. Boshuisen K, Arzimanoglou A, Cross JH, Uiterwaal CS, Polster T, van Nieuwenhuizen O, Braun KP. Timing of antiepileptic drug withdrawal and long-term seizure outcome after paediatric epilepsy surgery (TimeToStop): a retrospective observational study. Lancet Neurol 2012, 11:784-791. 10.1016/S1474-4422(12)70165-5, 22841352.
32. Berg AT, Langfitt JT, Spencer SS, Vickrey BG. Stopping antiepileptic drugs after epilepsy surgery: a survey of U.S. epilepsy center neurologists. Epilepsy Behav 2007, 10:219-222. 10.1016/j.yebeh.2006.12.001, 17251061.
33. Tellez-Zenteno JF, Ronquillo LH, Jette N, Burneo JG, Nguyen DK, Donner EJ, Sadler M, Javidan MM, Gross DW, Wiebe S. Discontinuation of antiepileptic drugs after successful epilepsy surgery. a Canadian survey. Epilepsy Res 2012, 102:23-33. 10.1016/j.eplepsyres.2012.04.018, 22595484.
34. Ziemba KS, Wellik KE, Hoffman-Snyder C, Noe KH, Demaerschalk BM, Wingerchuk DM. Timing of antiepileptic drug withdrawal in adult epilepsy patients after neocortical surgical resection: a critically appraised topic. Neurologist 2011, 17:176-178. 10.1097/NRL.0b013e318217368e, 21532391.
35. Swisher CB, Sinha SR. Survey of current practices among US epileptologists of antiepileptic drug withdrawal after epilepsy surgery. Epilepsy Behav 2013, 26:203-206. 10.1016/j.yebeh.2012.11.053, 23305782.
36. Kahlenberg CA, Fadul CE, Roberts DW, Thadani VM, Bujarski KA, Scott RC, Jobst BC. Seizure prognosis of patients with low-grade tumors. Seizure 2012, 21:540-545. 10.1016/j.seizure.2012.05.014, 22726817.
37. Khan RB, Onar A. Seizure recurrence and risk factors after antiepilepsy drug withdrawal in children with brain tumors. Epilepsia 2006, 47:375-379. 10.1111/j.1528-1167.2006.00431.x, 16499763.
38. Das RR, Artsy E, Hurwitz S, Wen PY, Black P, Golby A, Dworetzky B, Lee JW. Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomas. J Neurooncol 2012, 107:565-570. 10.1007/s11060-011-0779-y, 22212850.
39. van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011, 12:583-593. 10.1016/S1470-2045(11)70057-2, 21474379.
40. de Groot M, Reijneveld JC, Aronica E, Heimans JJ. Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment. Brain 2012, 135:1002-1016. 10.1093/brain/awr310, 22171351.
41. Schmidt D. AED discontinuation may be dangerous for seizure-free patients. J Neural Transm 2011, 118:183-186. 10.1007/s00702-010-0527-z, 21165660.